CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, general and gastrointestinal surgeons and other allied healthcare professionals involved in the treatment of biliary tract cancers.
  
  LEARNING OBJECTIVES

  • Apply clinical research findings in the formation of evidence-based therapeutic approaches for the treatment of unresectable and metastatic biliary tract cancers (BTCs).
  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for patients with advanced BTCs, and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibody-based approaches into the treatment of these diseases.
  • Recognize the molecular heterogeneity of cholangiocarcinomas and other BTCs, and appreciate the biological rationale for efforts to exploit documented abnormalities in patients with these diseases.
  • Assess key data sets supporting the FDA approvals of FGFR inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement to optimally select and sequence these agents in the care of appropriately identified patients.
  • Develop an understanding of available clinical trial findings supporting the use of IDH inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation to determine the applicability of this therapeutic strategy in current clinical practice.
  • Evaluate available clinical trial findings with HER2-directed therapies for HER2-positive BTCs, and contemplate the current and future utility of these agents and regimens in the care of appropriately selected patients.
  • Recall available data with investigational agents and strategies currently in clinical testing for BTCs, and refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/InsidetheIssue2023/BTC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/InsidetheIssue2023/BTC/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/InsidetheIssue2023/BTC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/InsidetheIssue2023/BTC.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Lipika Goyal, MD, MPhil
  Director of Gastrointestinal Oncology
  Stanford Cancer Center
  Associate Professor
  Stanford University School of Medicine
  Palo Alto, California
  
  Advisory Board and Consulting Agreements: AbbVie Inc, Alentis Therapeutics AG, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Cogent Biosciences, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Incyte Corporation, Kinnate Biopharma, Merck, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Milind Javle, MD
  Professor
  Department of Gastrointestinal Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Meclon Pharmaceuticals, MSD, Novartis, OncoSil Medical Ltd, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, TransThera Sciences; Contracted Research: Agios Pharmaceuticals Inc, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Meclon Pharmaceuticals, MSD, Novartis, OncoSil Medical Ltd, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, TransThera Sciences.
  
  SURVEY PARTICIPANTS — Ghassan Abou-Alfa, MD, MBA — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Autem Therapeutics, Berry Genomics, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, FibroGen Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Neogene Therapeutics, Novartis, Servier Pharmaceuticals LLC, Tempus, Thetis Pharmaceuticals, Vector Pharma, Yiviva; Contracted Research: Agenus Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Puma Biotechnology Inc, QED Therapeutics, Yiviva; Nonrelevant Financial Relationship: Parker Institute for Cancer Immunotherapy. Mitesh J Borad, MD — Advisory Committee: Cadila Pharmaceuticals, Compass Therapeutics, Diffusion Pharmaceuticals, Eisai Inc, Elevar Therapeutics, Exelixis Inc, Imugene, Imvax Inc, Jazz Pharmaceuticals Inc, KaliVir Immunotherapeutics, Kriya Therapeutics, Merck, OncoMyx Therapeutics, Revolution Medicines, Tempus, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Biond Biologics, Compass Therapeutics, Dragonfly Therapeutics, HiFiBiO Therapeutics, JSI Bio, Quaint Pharmaceuticals, Servier Pharmaceuticals LLC, Turnstone Biologics, ZielBio; Stock Options/Ownership — Public Company: Abeona Therapeutics, ADC Therapeutics, Assertio, bluebird bio, Homology Medicines Inc, Intercept Pharmaceuticals Inc; Nonrelevant Financial Relationship: George Clinical. John Bridgewater, MD, PhD — No relevant conflicts of interest to disclose. Robin (Katie) Kelley, MD — Advisory Committee (Payments to Insitution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements (Payments to Self): Compass Therapeutics, Exact Sciences Corporation, J-Pharma Co Ltd, Kinnate Biopharma, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research (Payment to Institution for Trial Conduct): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Partner Therapeutics, QED Therapeutics, Servier Pharmaceuticals LLC, Surface Oncology, Taiho Oncology Inc, Tyra Biosciences; Independent Data Monitoring Committee (Unpaid Service): Genentech, a member of the Roche Group, Merck.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Seagen Inc, and Taiho Oncology Inc.
  
  Release date: December 2023
  Expiration date: December 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.